Patents are currently in place that prevent companies from making a generic version of Invokana (canagliflozin). After the first patent expires in July 2024, however, this situation may change. Although canagliflozin is often referred to as the "generic name" for Invokana, it is simply the active ingredient in this product and not a generic version of it.
Invokana is manufactured by Janssen Pharmaceuticals, Inc. At this time, generic Invokana is not available.
When Will a Generic Version Be Available?
The first patent for Invokana is set to expire in July 2024. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This includes such things as lawsuits or other patents for new Invokana uses. Once the patents expire, there may be several companies that manufacture a generic Invokana drug.
Is Canagliflozin a Generic Invokana?
No -- canagliflozin is the active ingredient in Invokana, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed November 26, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click